Abstract 2278P
Background
The heterogeneity of the tumor microenvironment is a major barrier for effective cancer therapies. Similar to the immune tumor microenvironment the stromal environment, composed of cancer-associated fibroblasts (CAFs), pericytes, adipocytes and endothelial cells, is also heterogeneous. Multiple studies showed that CAFs contain heterogenous cell populations with opposing pro and anti-tumoral function. The heterogeneity of endothelial cells (ECs) is less well described largely due to the relative low frequencies in tumor tissues compare to CAFs. We set out to study the heterogeneity of the tumor microenvironment using truly single-cell spatial transcriptomic by the 10x Genomics Xenium platform.
Methods
We analyzed 20 human breast tumors by Xenium single-cell analyzes using fluorescent in situ sequencing (FISSEQ). We used the available breast panel that contains 280 genes, with 8 probes for each gene. The analysis of the data was preformed using the Seurat pipeline in R (version 4.9.9.9039).
Results
We could readily identify blood vessel structures that surrounded PECAM1/VWF positive cells. After multiple clustering we identified five types of endothelial cells with divergent gene expression profiles. We defined the following clusters of ECs: 1) Proliferating ECs, 2) CXCL12+ ECs, 3) POSTNHi/VWFHi ECs, 4) TPD52Hi ECs and POSTNLow/VWFHi ECs. The endothelial cells also showed spatial variations in distribution. Data on EC subtypes will correlation and other cell types and cell neighborhoods will be presented.
Conclusions
ECs in breast cancer tumors are highly heterogeneous and can be further classified into functionally divergent subtypes, potentially contributing to the heterogenous responses observed to treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CHUV.
Funding
CHUV.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2252P - KRAS G12C inhibition using MRTX849: A novel radio-sensitizing partner
Presenter: Marina Milic
Session: Poster session 08
2253P - RAS-precision medicine trans-atlantic partnership: Comparative analysis of KRAS codon 12 and 13 mutations in non-small cell lung cancer
Presenter: Helen Adderley
Session: Poster session 08
2254P - Persisting RAS addiction: A therapeutic vulnerability in the context of KRAS G12C inhibitor resistance
Presenter: George Morrissey
Session: Poster session 08
2255P - Clinicogenomic landscapes and hallmarks of KRAS amplification in human cancers
Presenter: Biagio Ricciuti
Session: Poster session 08
2256P - The microenvironment of normal mucosa could predict recurrence in the stage II/III colorectal cancer: Multicenter, multiomics study
Presenter: Yeonghak Bang
Session: Poster session 08
2257P - Stereotactic body radiation therapy and atezolizumab combination: Results of the international multi-centre SABR-PDL1 phase II trial colorectal cohort
Presenter: Antonin Levy
Session: Poster session 08
2258P - Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: Drug screen optimization and correlation with patient response
Presenter: Lidwien Smabers
Session: Poster session 08
2259P - An artificial neural network system to predict the fraction of type I polarized macrophage
Presenter: Tongji Xie
Session: Poster session 08
2260P - Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Presenter: Andrea Paccone
Session: Poster session 08
2261P - A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2- breast cancer patients
Presenter: Nadia Dandachi
Session: Poster session 08